 |
|
JAMA-EXPRESS
Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 DiabetesA Randomized Controlled Trial
Hisao Ogawa, MD, PhD;
Masafumi Nakayama, MD, PhD;
Takeshi Morimoto, MD, PhD;
Shiro Uemura, MD, PhD;
Masao Kanauchi, MD, PhD;
Naofumi Doi, MD, PhD;
Hideaki Jinnouchi, MD, PhD;
Seigo Sugiyama, MD, PhD;
Yoshihiko Saito, MD, PhD; for the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators
JAMA. 2008;300(18):2134-2141. Published online November 9, 2008 (doi: 10.1001/jama.2008.623).
Context Previous trials have investigated the effects of low-dose aspirin on primary prevention of cardiovascular events, but not in patients with type 2 diabetes.
Objective To examine the efficacy of low-dose aspirin for the primary prevention of atherosclerotic events in patients with type 2 diabetes.
Design, Setting, and Participants Multicenter, prospective, randomized, open-label, blinded, end-point trial conducted from December 2002 through April 2008 at 163 institutions throughout Japan, which enrolled 2539 patients with type 2 diabetes without a history of atherosclerotic disease and had a median follow-up of 4.37 years.
Interventions Patients were assigned to the low-dose aspirin group (81 or 100 mg per day) or the nonaspirin group.
Main Outcome Measures Primary end points were atherosclerotic events, including fatal or nonfatal ischemic heart disease, fatal or nonfatal stroke, and peripheral arterial disease. Secondary end points included each primary end point and combinations of primary end points as well as death from any cause.
Results A total of 154 atherosclerotic events occurred: 68 in the aspirin group (13.6 per 1000 person-years) and 86 in the nonaspirin group (17.0 per 1000 person-years) (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.58-1.10; log-rank test, P = .16). The combined end point of fatal coronary events and fatal cerebrovascular events occurred in 1 patient (stroke) in the aspirin group and 10 patients (5 fatal myocardial infarctions and 5 fatal strokes) in the nonaspirin group (HR, 0.10; 95% CI, 0.01-0.79; P = .0037). A total of 34 patients in the aspirin group and 38 patients in the nonaspirin group died from any cause (HR, 0.90; 95% CI, 0.57-1.14; log-rank test, P = .67). The composite of hemorrhagic stroke and significant gastrointestinal bleeding was not significantly different between the aspirin and nonaspirin groups.
Conclusion In this study of patients with type 2 diabetes, low-dose aspirin as primary prevention did not reduce the risk of cardiovascular events.
Trial Registration clinicaltrials.gov Identifier: NCT00110448
Author Affiliations: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan (Drs Ogawa, Nakayama, and Sugiyama); Center for Medical Education, Kyoto University Graduate School of Medicine, Kyoto, Japan (Dr Morimoto); First Department of Internal Medicine, Nara Medical University, Nara, Japan (Drs Uemura, Kanauchi, Doi, and Saito); and Jinnouchi Hospital, Kumamoto (Dr Jinnouchi).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Aspirin for Primary Prevention of Cardiovascular Events in Diabetes: Still an Open Question
Antonio Nicolucci
JAMA. 2008;300(18):2180-2181.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Aspirin for the Primary Prevention of Cardiovascular Events: A systematic review and meta-analysis comparing patients with and without diabetes
Calvin et al.
Diabetes Care 2009;32:2300-2306.
ABSTRACT
| FULL TEXT
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
De Berardis et al.
BMJ 2009;339:b4531-b4531.
ABSTRACT
| FULL TEXT
Aspirin for primary prevention of cardiovascular disease?
DTB 2009;47:122-125.
ABSTRACT
| FULL TEXT
ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association Endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research.
Redberg et al.
J Am Coll Cardiol 2009;54:1364-1405.
FULL TEXT
ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease): Developed in Collaboration With the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: Endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research
WRITING COMMITTEE MEMBERS et al.
Circulation 2009;120:1296-1336.
FULL TEXT
Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach
O'Keefe et al.
Mayo Clin Proc. 2009;84:741-757.
ABSTRACT
| FULL TEXT
Sarpogrelate Versus Aspirin in Secondary Prevention of Cerebral Infarction: Differential Efficacy in Diabetes?: Subgroup Analysis From S-ACCESS
Shinohara et al.
Stroke 2009;40:2862-2865.
ABSTRACT
| FULL TEXT
Aspirin for prevention of myocardial infarction and stroke: is the right dose 81 or 160 mg/day?
Dalen
J Am Coll Cardiol 2009;53:2010-2010.
FULL TEXT
Aspirin and Secondary Prevention in Peripheral Artery Disease: A Perspective for the Early 21st Century
McDermott and Criqui
JAMA 2009;301:1927-1928.
FULL TEXT
COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment
Pulcinelli et al.
Eur Heart J 2009;30:1279-1286.
ABSTRACT
| FULL TEXT
Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)
Kasanuki et al.
Eur Heart J 2009;30:1203-1212.
ABSTRACT
| FULL TEXT
Association Between Increased Platelet P-Selectin Expression and Obesity in Patients With Type 2 Diabetes: A BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy
Schneider et al.
Diabetes Care 2009;32:944-949.
ABSTRACT
| FULL TEXT
The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2009;53:1326-1337.
FULL TEXT
Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions
Angiolillo
Diabetes Care 2009;32:531-540.
FULL TEXT
Aspirin Therapy in Women: Back to the ABCs
Mora
Circ Cardiovasc Qual Outcomes 2009;2:63-64.
FULL TEXT
Diabetes Quality Improvement: Rigor and Ridicule
Elasy
Clin. Diabetes 2009;27:49-51.
FULL TEXT
All you need to read in the other general journals
BMJ 2008;337:a2571-a2571.
FULL TEXT
Does Aspirin Prevent Cardiovascular Events in Patients with Diabetes?
Journal Watch Cardiology 2008;2008:2-2.
FULL TEXT
Aspirin, Cardiovascular Disease, and Type 2 Diabetes
JWatch General 2008;2008:3-3.
FULL TEXT
Aspirin for Primary Prevention of Cardiovascular Events in Diabetes: Still an Open Question
Nicolucci
JAMA 2008;300:2180-2181.
FULL TEXT
|
